Memphasys

Memphasys P/B

The P/B (Price-to-Book Ratio) of Memphasys (MEM.AX) as of Oct 18, 2026 is 4.73. In the previous year, P/B (Price-to-Book Ratio) was 3.71 — a change of 27.43% (higher).

P/B

4.73

YoY

27.43%

Last updated:

P/B (Price-to-Book Ratio) of Memphasys is 2026 4.73 . P/B (Price-to-Book Ratio) of Memphasys was 2025 3.71 . It decreases by 27.43% higher compared to the previous year.

The Memphasys P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
3.28 AUD
Jan 1, 2020
2.04 AUD
Jan 1, 2021
2.32 AUD
Jan 1, 2022
2.61 AUD
Jan 1, 2023
2.70 AUD
Jan 1, 2024
2.91 AUD
Jan 1, 2025
3.71 AUD
Jan 1, 2026
4.73 AUD
The Memphasys P/B history
YEARP/BYoY
4.73+27.43%
3.71+27.38%
2.91+8.00%
2.70+3.55%
2.61+12.56%
2.32+13.35%
2.04-37.77%
3.28-44.80%
5.95-112.00%
-49.55-467.36%
13.49-49.47%
26.70-232.98%
-20.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

P/B (Price-to-Book Ratio) of Memphasys is 4.73 in 2026.

P/B (Price-to-Book Ratio) of Memphasys changed from 3.71 to 4.73, representing a 27.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Memphasys since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Memphasys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Memphasys

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Memphasys